Wird geladen...
P08.43 Bevacizumab discontinuation and bevacizumab re-challenge in glioblastoma patients
BACKGROUND AND OBJECTIVE: . In glioblastoma (GBM) patients who benefit from bevacizumab, it is unknown how long this treatment should be continued and whether it may be safely stopped. The aim of the present study was to describe the outcome of 36 responding GBM patients in whom bevacizumab was disc...
Gespeichert in:
| Veröffentlicht in: | Neuro Oncol |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Oxford University Press
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5782672/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now188.176 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|